Pfizer (PFE) reported Q3 FY 2019 earnings of $0.75 per share (versus $0.77 in Q3 FY 2018), beating analysts’ consensus estimate of $0.61.
The company’s quarterly revenues amounted to $12.680 bln (-4.6% y/y), beating analysts’ consensus estimate of $12.365 bln.
The company also raised guidance for FY 2019, projecting EPS of $2.94-3.00 (versus its prior guidance of $2.76-2.86 and analysts’ consensus estimate of $2.82) and revenue of $51.2-52.2 bln (versus its prior guidance of $50.5-52.5 bln and analysts’ consensus estimate of $51.47 bln).
PFE rose to $38.40 (+3.00%) in pre-market trading.